Method for obtaining sterile human amniotic fluid and uses thereof
Provided herein is a method for sterilely filtering amniotic fluid from selected caesarean sections of an individual. The amniotic fluid is first centrifuged at 5,000 to 10,000 rpm for 30 to 60 minutes and filtered through filters with about 5 to about 10 μm pore size. Next, the fluid is sequentially filtered through a series of membrane filters with the pore sizes 1 μm and 0.45 or/and 0.2 μm. The filtrate is then aseptically transferred to and sealed in syringes or vials. The fluid is subsequently lyophilized to obtain the lyophilisate of amniotic fluid. Amniotic fluid is reconstituted by adding sterile water to the lyophilisate, and the reconstituted fluid is used for wound healing, cosmetic, orthopedic or ophthalmic applications, particularly for the treatment of dry eyes.
1. A method for obtaining sterilely filtered, cell-free, non-irradiated human amniotic fluid, the method comprising serially filtering the human amniotic fluid, the steps of the method comprising:
collecting amniotic fluid under sterile conditions from a woman;
removing cells, large particles and other undissolvables from the human amniotic fluid by centrifuging the human amniotic fluid to obtain clarified amniotic fluid; and
serially filtering the clarified amniotic fluid through multiple filters selected from the group consisting of depth filters and membrane filters with a pore size of 0.45 μm and 0.2 μm to obtain a sterile filtrate that is not irradiated.
2. The method of claim 1 , wherein the step of collecting amniotic fluid from a woman under sterile conditions comprises the use of an ultrasound device to provide guidance for the process of obtaining human amniotic fluid from the woman.
3. The method of claim 2 , wherein the step of collecting amniotic fluid under sterile conditions comprises the use of a sterile collection container, wherein the sterile collection container comprises a pump with a suction device.
4. The method of claim 3 , wherein the suction device is a low suction device or a spring loaded low suction device.
5. The method of claim 3 , wherein the suction device is fluidly connected to an internal balloon.
6. The method of claim 5 , further comprising manually pumping up the internal balloon in the sterile collection container using the low suction device to allow a low-level suction and collection of the amniotic fluid.
7. The method of claim 1 , wherein the step of removing cells, large particles and other undissolvables from the human amniotic fluid comprises depth filtering the human amniotic fluid.
8. The method of claim 1 , wherein prior to the step of filtering the clarified amniotic fluid through multiple filters selected from the group consisting of depth filters and membrane filters with a pore size of 0.45 μm and 0.2 μm, the clarified amniotic fluid is filtered through one or more filters with a pore size of between about 5 to 10 μm, and/or through one or more filters with a pore size of about 1.0 μm.
9. The method of claim 8 , wherein the filters with the pore size of about 5 to 10 μm are cellulose ester filters, glass fiber filters, nylon capsule filters or nylon cartridge filters.
10. The method of claim 8 , wherein the filters with the pore size of about 1.0 μm are capsule filters or cartridge filters.
11. The method of claim 8 , wherein the filters with the pore size of about 1.0 μm are poly ether sulfone, poly vinylidene fluoride or cellulose acetate membrane filters.
12. The method of claim 1 , wherein the filters with the pore size of 0.45 μm and 0.2 μm are capsule filters or cartridge filters.
13. The method of claim 12 , wherein the filters with the pore size of 0.45 μm and 0.2 μm are poly ether sulfone, poly vinylidene fluoride or cellulose acetate membrane filters.
14. The method of claim 1 , wherein the sterile filtered human amniotic fluid contains one or more of human growth hormone, transforming growth factor beta 1, vascular endothelial growth factor, epidermal growth factor, transforming growth factor beta 3, and growth differentiation factor 11.
15. The method of claim 1 , further comprising lyophilizing the sterile amniotic fluid to obtain a lyophilisate thereof.
16. A sterile filtered, cell-free, non-irradiated human amniotic fluid produced by the method of claim 1 .
17. A pharmaceutical formulation for wound healing, cosmetic, orthopedic or ophthalmic applications, comprising the sterile filtered, cell-free, non-irradiated amniotic fluid of claim 1 .
18. A kit to obtain sterile filtered human amniotic fluid from a women using the method of claim 1 , comprising:
a three-way stopcock;
a sterile blunt tip needle aseptically attached to the three-way stopcock;
a luer lock syringe aseptically connected to the three-way stopcock;
a sterile tubing aseptically connected to the three-way stopcock;
a collection container or a collection container comprising a pump with suction device connected with the sterile tubing;
a set of filters having a pore size of from about 5 μm to about 10 μm;
a set of capsule or cartridge filters having a pore size of about 1 μm;
a set of capsule or cartridge filters having a pore size of about 0.45 μm or/and 0.2 μm;
a set of sterile syringes or vials to store the sterile filtered amniotic fluid; and
operating instructions on using the kit to obtain sterile filtered amniotic fluid.
19. The kit of claim 18 , wherein the filters having the pore size of between about 5 μm to about 10 m and the capsule or cartridge filters are poly ether sulfone, poly vinylidene fluoride or cellulose acetate membrane filters.
20. The method of claim 1 , where in the sterile filtered, cell-free, non-irradiated human amniotic fluid has a 10 6 sterility assurance level.